KTTA Valuation

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

KTTA Relative Valuation

KTTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KTTA is overvalued; if below, it's undervalued.

Historical Valuation

Pasithea Therapeutics Corp (KTTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 12.33. The fair price of Pasithea Therapeutics Corp (KTTA) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.40

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.14

P/B

Median3y

0.34

Median5y

1.63

-310.05

FCF Yield

Median3y

-211.67

Median5y

-175.73

Competitors Valuation Multiple

The average P/S ratio for KTTA's competitors is 0.05, providing a benchmark for relative valuation. Pasithea Therapeutics Corp Corp (KTTA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

KTTA.O

Pasithea Therapeutics Corp

Loss

Average P/S: 0.05

3.79M